Hims & Hers Health (HIMS)

NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-10-23

$27.71-4.87%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Hims & Hers Health’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

0.0%

+10% or more+5%0%−5%−10% or less

0.30 → 0.30 EPS · FY ending Dec 31, 2027 · 9 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 24, 2026 to Oct 24, 2026: (new ÷ prior − 1). Contributor count changed from 9 to 9; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q3
Revenue	$880M–$900M	—
EBITDA	$75M–$95Mnon-GAAP	—
FY 2026 · Q4
Revenue	—	953.41M
EPS	—	0.116
FY 2026 · Annual
Revenue	$3.1B–$3.3B	3.21B
EPS	—	-0.589
EBITDA	$275M–$325Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	4.05B
EPS	—	0.298

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash from operations improves toward prior levels	Cash flow and profit are still weak but improving.	Broken	Cash from operations falls below $89 million quarterly	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Operating income improves from negative $78 million	A supporting condition in Hims & Hers Health's published investment case. The stated target is Operating income improves toward breakeven.	Improving	Operating income remains below negative $78 million	Operating income: $-97.192M FY2026-Q2; GAAP. Published target: Operating income improves toward breakeven. Target period is not explicitly aligned with this observation. Source published Aug 10, 2026-97,192,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 61e84585-f7f5-4101-bd04-4f4e685e4317. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue reaches $2.8-$3.0 billion in 2026	A primary condition in Hims & Hers Health's published investment case. The stated target is >= $2.8 billion.	Intact	Revenue falls below $2.8 billion in FY26	Revenue: $753.214M FY2026-Q2; GAAP. Published target: >= $2.8 billion. Target period is not explicitly aligned with this observation. Source published Aug 10, 2026753,214,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 61e84585-f7f5-4101-bd04-4f4e685e4317. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Subscriber base grows to at least 2.6 million	A primary condition in Hims & Hers Health's published investment case. The stated target is >= 2.6 million subscribers.	Intact	Subscriber count falls below 2.6 million	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 4 of last 4 quarters. Subscriber count grew from 2.44 million in Q2 2025 to 2.89 million in Q2 2026, a 19% increase. Monthly revenue per subscriber also increased, supporting recurring revenue growth. Management is delivering on expanding subscriber base and engagement. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$0.30

Unavailable → $0.30 · observed estimates

FY2027 revenue$4.05B

Unavailable → $4.05B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	3 / 2
2026-07-25	Unavailable	Unavailable	3 / 2
2026-07-26	Unavailable	Unavailable	3 / 3
2026-07-27	Unavailable	Unavailable	3 / 3
2026-07-28	Unavailable	Unavailable	3 / 3
2026-07-29	Unavailable	Unavailable	3 / 3
2026-07-30	Unavailable	Unavailable	3 / 3
2026-07-31	Unavailable	Unavailable	3 / 4
2026-08-01	Unavailable	Unavailable	3 / 4
2026-08-02	Unavailable	Unavailable	3 / 3
2026-08-03	Unavailable	Unavailable	3 / 3
2026-08-04	Unavailable	Unavailable	3 / 4
2026-08-05	Unavailable	Unavailable	3 / 4
2026-08-06	Unavailable	Unavailable	3 / 4
2026-08-07	Unavailable	Unavailable	3 / 4
2026-08-08	Unavailable	Unavailable	3 / 4
2026-08-09	Unavailable	Unavailable	3 / 3
2026-08-10	Unavailable	Unavailable	3 / 4
2026-08-12	$0.58	$4,001,620,250	10 / 12
2026-08-13	$0.58	$4,001,620,250	10 / 12
2026-08-14	Unavailable	Unavailable	3 / 4
2026-08-15	$0.47	$3,525,020,974	6 / 7
2026-08-16	$0.47	$3,525,020,974	6 / 7
2026-08-17	$0.47	$3,525,020,974	6 / 7
2026-08-18	$0.47	$3,525,020,974	6 / 7
2026-08-19	$0.47	$3,525,020,974	6 / 7
2026-08-20	$0.40	$3,924,282,112	9 / 10
2026-08-21	$0.36	$3,983,282,112	9 / 10
2026-08-22	$0.36	$3,983,282,112	9 / 10
2026-08-23	$0.36	$3,983,282,112	9 / 10
2026-08-24	$0.36	$3,983,282,112	8 / 10
2026-08-25	$0.36	$4,028,753,541	8 / 11
2026-08-26	$0.36	$4,028,753,541	8 / 11
2026-08-27	$0.36	$4,028,753,541	8 / 11
2026-08-28	$0.36	$4,028,753,541	8 / 11
2026-08-29	$0.36	$4,028,753,541	8 / 11
2026-08-30	$0.36	$4,028,753,541	8 / 11
2026-08-31	$0.36	$4,028,753,541	8 / 11
2026-09-01	$0.36	$4,028,753,541	8 / 11
2026-09-02	$0.36	$4,028,753,541	8 / 11
2026-09-03	$0.36	$4,028,753,541	8 / 11
2026-09-04	$0.30	$4,042,627,255	8 / 11
2026-09-05	$0.30	$4,042,627,255	8 / 11
2026-09-06	$0.30	$4,042,627,255	8 / 11
2026-09-07	$0.30	$4,042,627,255	8 / 11
2026-09-08	$0.30	$4,042,627,255	8 / 11
2026-09-09	$0.30	$4,042,627,255	8 / 11
2026-09-10	$0.30	$4,042,627,255	8 / 11
2026-09-11	$0.30	$4,042,627,255	8 / 11
2026-09-12	$0.30	$4,047,052,105	8 / 11
2026-09-13	$0.30	$4,047,052,105	8 / 11
2026-09-14	$0.30	$4,047,052,105	8 / 11
2026-09-15	$0.30	$4,047,052,105	8 / 11
2026-09-16	$0.30	$4,047,052,105	8 / 11
2026-09-17	$0.30	$4,047,052,105	9 / 12
2026-09-18	$0.30	$4,047,052,105	9 / 12
2026-09-19	$0.30	$4,047,052,105	9 / 12
2026-09-20	$0.30	$4,047,052,105	9 / 12
2026-09-21	$0.30	$4,047,052,105	9 / 12
2026-09-22	$0.30	$4,047,052,105	9 / 12
2026-09-23	$0.30	$4,047,052,105	9 / 12
2026-09-24	$0.30	$4,047,052,105	9 / 12
2026-09-25	$0.30	$4,047,052,105	9 / 12
2026-09-26	$0.30	$4,047,052,105	9 / 11
2026-09-27	$0.30	$4,047,052,105	9 / 11
2026-09-28	$0.30	$4,047,052,105	9 / 11
2026-09-29	$0.30	$4,045,172,724	9 / 11
2026-09-30	$0.30	$4,045,172,724	9 / 11
2026-10-01	$0.30	$4,045,172,724	9 / 11
2026-10-02	$0.30	$4,045,172,724	9 / 11
2026-10-03	$0.30	$4,045,186,844	9 / 11
2026-10-04	$0.30	$4,045,186,844	9 / 11
2026-10-05	$0.30	$4,045,186,844	9 / 11
2026-10-06	$0.30	$4,045,186,844	9 / 11
2026-10-07	$0.30	$4,045,186,844	9 / 11
2026-10-08	$0.30	$4,045,186,844	9 / 11
2026-10-09	$0.30	$4,045,186,844	9 / 11
2026-10-10	$0.30	$4,045,186,844	9 / 11
2026-10-11	$0.30	$4,045,186,844	9 / 11
2026-10-12	$0.30	$4,045,186,844	9 / 11
2026-10-13	$0.30	$4,045,186,844	9 / 11
2026-10-14	$0.30	$4,045,186,844	9 / 11
2026-10-15	$0.30	$4,045,186,844	9 / 11
2026-10-16	$0.30	$4,045,186,844	9 / 11
2026-10-17	$0.30	$4,045,186,844	9 / 11
2026-10-18	$0.30	$4,045,186,844	9 / 11
2026-10-19	$0.30	$4,045,186,844	9 / 11
2026-10-20	$0.30	$4,045,186,151	9 / 11
2026-10-21	$0.30	$4,045,188,772	9 / 11
2026-10-22	$0.30	$4,045,188,772	9 / 11
2026-10-23	$0.30	$4,045,188,772	9 / 11
2026-10-24	$0.30	$4,045,188,772	9 / 11

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	12	1
2026-06-01	4	12	1
2026-07-01	3	12	1
2026-08-01	3	12	1
2026-09-01	3	13	1
2026-10-01	3	12	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 12 Hold · 1 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash from operations improves toward prior levelsPublished status: Broken
Operating income improves from negative $78 millionOperating income: $-97.192M
Revenue reaches $2.8-$3.0 billion in 2026Revenue: $753.214M
Subscriber base grows to at least 2.6 millionDirect metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.1%Typical daily move · historical

Downside history

-70.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Hims & Hers Health outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk growth business, not yet a proven durable compounder, because it remains loss-making. The multi-year thesis is still active: revenue growth and international expansion are on track, while technology investment has mixed evidence and recent financial performance is weak.

What's priced into Hims & Hers Health

The valuation evidence is mixed: HIMS is described as cheap versus peers, while the model also shows a 0.75 premium versus peers and a negative expectations gap. Overall, priced-in risk is tagged as justified, with no fragility flags, but the evidence does not support a clear claim that expectations are either low or undemanding.

What the fundamentals likely do

Near term, revenue growth has been strong, and management raised its 2026 revenue guidance while reaffirming its 2030 goal. However, the latest earnings miss, a record of recent misses, and volatile management make execution less certain; technology investment has not yet shown measured cost savings.

What Hims & Hers Health hinges on

The multi-year case depends on sustaining revenue growth, turning international expansion into lasting business progress, and showing that technology investment improves efficiency. Near term, a reversal of recently raised guidance would damage credibility, while weaker jobs data could add pressure; continued strength from healthcare bellwethers would support the sector backdrop.